• Price Band fixed at ₹ 319 to ₹ 336 per equity share of face value of ₹ 2 each of Global Health Limited
• (“Equity Shares”)
• Bid /Offer Opening Date – Thursday, November 03, 2022 and Bid/ Offer Closing Date – Monday, November 07, 2022

Global Health Limited (the “Company”), which currently operates a network of five hospitals (in Gurugram, Indore, Ranchi, Lucknow and Patna) under the brand ‘Medanta’ and one hospital (in Noida) which is under construction, will open its initial public offering on November 03, 2022.

The Price Band of the offer has been fixed at ₹ 319 to ₹ 336 per Equity Share of face value ₹ 2 each. Bids can be made for a minimum of 44 Equity Shares and in multiples of 44 equity shares thereafter.

The initial public offering comprises a Fresh Issue aggregating up to ₹5,000.00 million and an Offer for Sale of up to 50,761,000 Equity Shares by the Selling Shareholders comprising of up to 50,661,000 Equity Shares by Anant Investments, an affiliate of The Carlyle Group, and up to 100,000 Equity Shares by Sunil Sachdeva (jointly with Suman Sachdeva).

The Company intends to use the proceeds of the fresh issue for Investment in two of its subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment/prepayment of borrowings, in full or part, of such subsidiaries, of ₹3,750.00 million. The balance amount of the net issue proceeds will be used for general corporate purposes.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957 read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure)  Regulations, 2018 (“SEBI ICDR Regulations”) and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “QIB Portion”), provided that the  Company and the Investor Selling Shareholder may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis, in accordance with the SEBI ICDR Regulations (the “Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion.

Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from the Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders (“Non-Institutional Portion”) of which (a) one-third shall be available for allocation to Bidders with an application size of more than ₹200,000 and up to ₹1,000,000 and (b) two-thirds shall be available for allocation to Bidders with an application size of more than ₹1,000,000 provided that under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price, and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders (“Retail Portion”) in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders, other than Anchor Investors, are required to mandatorily utilize the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA accounts and UPI ID (defined hereinafter) (in case of UPI Bidders using UPI Mechanism (defined hereinafter)), if applicable, in which the corresponding Bid Amounts will be blocked by the self-certified syndicate banks (“SCSBs”) or the Sponsor Banks under the UPI Mechanism, as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process.

The Equity Shares offered through Red Herring Prospectus are proposed to be listed on BSE and NSE.

Kotak Mahindra Capital Company Limited, Credit Suisse Securities (India) Private Limited, Jefferies India Private Limited and JM Financial Limited are the Book Running Lead Managers.

Disclaimer:

Disclaimer clause of SEBI: SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 437 of the Red Herring Prospectus for the full text of the disclaimer clause of SEBI.

Disclaimer clause of NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 443 of the Red Herring Prospectus for the full text of the disclaimer clause of NSE Limited.

Disclaimer clause of BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Red Herring Prospectus has been cleared or approved by BSE Limited nor does it certify the correctness or completeness of any of the contents of the Red Herring Prospectus. The investors are advised to refer to page 443 of the Red Herring Prospectus for the full text of the disclaimer clause of the BSE Limited.

Global Health Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its equity shares (“Offer”) and has filed a Red Herring Prospectus with the Registrar of Companies, Delhi & Haryana at Delhi. The Red Herring Prospectus is available on the website of the SEBI at www.sebi.gov.in, the website of the National Stock Exchange of India Limited at www.nseindia.com and the website of the BSE Limited at www.bseindia.com and the respective websites of the book running lead managers to the Offer, Kotak Mahindra Capital Company Limited at https://www.investmentbank.kotak.com, Jefferies India Private Limited at https://www.jefferies.com, Credit Suisse Securities (India) Private Limited at https://www.credit-suisse.com/in/en/investment-banking-apac/investment-banking-in-india/ipo.html and JM Financial Limited at www.jmfl.com. Investors should note that investment in equity shares involves a high degree of risk. For details, potential investors should refer to the Red Herring Prospectus which has been filed with the Registrar of Companies, Delhi & Haryana at Delhi in the future, including the section titled “Risk Factors”. Potential investors should not rely on the Draft Red Herring Prospectus filed with the SEBI in making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) in private transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering of the Equity Shares in the United States.